Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review
Open Access
- 14 October 2012
- journal article
- review article
- Published by Hindawi Limited in Chemotherapy Research and Practice
- Vol. 2012, 1-11
- https://doi.org/10.1155/2012/387172
Abstract
Colorectal cancer is the second most common malignancy among men and women in the United States, and the 5-year survival rate remains poor despite recent advances in chemotherapy and targeted agents. The mainstay of therapy for advanced disease remains the cytotoxic chemotherapy including 5-FU, irinotecan, and oxaliplatin. The USFDA approval and introduction of targeted therapies, including cetuximab and panitumumab (monoclonal antibodies targeting the epidermal growth factor receptor (EGFR)) and bevacizumab (monoclonal antibody targeting the vascular epithelial growth factor (VEGF)), has improved the median survival of patients with metastatic colorectal cancer to around 24 months. Clearly, better and more efficacious drugs are needed, and target-specific agents remain the future of cancer treatment. On this front, rapid advances are being made, which are likely to change the future of the management of metastatic colorectal cancer. However, absence of specific biomarkers for the use of targeted agents, in the subset of population who will benefit from the treatment, remains a major drawback. In this paper, we review agents that are in phases 1 and 2 clinical development, specifically targeting the EGFR and its subsequent downstream pathways.Keywords
Funding Information
- National Institutes of Health (1K12CA132783-01A1)
This publication has 88 references indexed in Scilit:
- PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal CancerClinical Colorectal Cancer, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibThe New England Journal of Medicine, 2012
- Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodellingBiochemical Society Transactions, 2012
- A Decade of Advances in Cytotoxic Chemotherapy for Metastatic Colorectal CancerClinical Colorectal Cancer, 2011
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- A Phase II Trial of Bevacizumab plus Everolimus for Patients with Refractory Metastatic Colorectal CancerThe Oncologist, 2011
- Targeting the RAF–MEK–ERK pathway in cancer therapyCancer Letters, 2009
- Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevantBritish Journal of Cancer, 2009
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal AntibodiesCancer Research, 2009
- Phase II Trial of Erlotinib and Capecitabine for Patients with Previously Untreated Metastatic Colorectal CancerClinical Colorectal Cancer, 2009